Why BDNF and NGF matter for cognition
Brain-derived neurotrophic factor and nerve growth factor are not particularly glamorous names, but the processes they govern sit at the very centre of how learning and memory work at a molecular level. Both belong to the neurotrophin family, signalling proteins that regulate the survival, development, and function of neurons throughout the nervous system.
BDNF is most strongly associated with activity-dependent plasticity: the process by which the brain physically rewires itself in response to experience. When a synapse fires repeatedly, BDNF release promotes the structural changes that stabilise that connection: thickening dendritic spines, strengthening receptor clustering, and enabling long-term potentiation, the cellular correlate of memory formation. Without adequate BDNF, these structural changes fail to consolidate, and learning becomes less efficient.
NGF plays an overlapping but distinct role, with particular importance for the cholinergic neurons of the basal forebrain that project to the hippocampus and cortex. These neurons are among the first to degrade in age-related cognitive decline and Alzheimer's pathology, and NGF is the principal trophic factor that keeps them healthy. A compound that reliably upregulates both of these proteins in relevant brain regions therefore has a mechanistically coherent claim to cognitive relevance — the question is whether the upregulation Semax produces is sufficient, and through what pathway it arrives.
The ACTH(4-10) lineage — how a stress hormone fragment became a neurotrophic agent
Semax is a heptapeptide (a seven-amino-acid chain) derived from the 4-10 fragment of adrenocorticotropic hormone, with a proline-glycine-proline tripeptide added to the C-terminus to confer stability against plasma proteases. The full ACTH molecule is a pituitary hormone that drives cortisol release from the adrenal glands. The 4-10 fragment retains no corticotropic activity whatsoever (it produces none of the stress-hormone effects of the parent molecule) but early Soviet research identified that it had measurable effects on memory and arousal in animal models.
The engineering question was how to make a research tool from this observation. Adding the C-terminal stabilising sequence solved the rapid degradation problem, producing a synthetic analogue that survives long enough after intranasal administration to reach the olfactory epithelium and begin the nose-to-brain transport sequence. What researchers found, and have replicated across multiple animal studies, is that this stabilised ACTH fragment does something the parent hormone does not: it potently stimulates BDNF and NGF gene expression in the hippocampus.
The mechanism through which an ACTH-derived peptide produces neurotrophic factor induction is not fully characterised at the receptor level. The most consistent evidence points to interaction with melanocortin receptors (particularly MC4R, which is expressed in hippocampal tissue) as the upstream event that initiates the cascade. But the receptor story remains an area of active investigation.
Step-by-step: from intranasal dose to hippocampal BDNF mRNA
When Semax solution is applied to the nasal mucosa, a fraction of the dose enters the olfactory epithelium and travels along olfactory receptor neurons toward the olfactory bulb. From the bulb, the compound distributes to limbic and cortical regions (including the hippocampus) through direct neural and perineural pathways that bypass the blood-brain barrier entirely.
Within the hippocampus, the molecular cascade begins relatively quickly. Published animal data demonstrates detectable increases in BDNF mRNA within approximately three hours of a single intranasal dose, a timeframe consistent with transcriptional activation rather than merely altered secretion of a pre-synthesised pool. The mRNA signal is the upstream event that precedes protein synthesis, meaning BDNF protein levels rise on a slightly longer timescale, with effects that have been reported to persist for at least 24 hours after a single administration.
NGF follows a similar pattern, with parallel increases in NGF mRNA in the hippocampus and cortex. The simultaneous induction of both neurotrophins from a single administration is one of the reasons Semax occupies a distinctive position in the research peptide field: compounds that upregulate both BDNF and NGF together engage complementary plasticity and cholinergic maintenance pathways simultaneously.
TrkB and TrkA receptor signalling downstream of BDNF/NGF release
Once released from neurons and glia, BDNF binds to its high-affinity receptor TrkB, triggering a phosphorylation cascade that activates multiple downstream pathways. The PI3K-Akt pathway promotes neuronal survival and protein synthesis. The MAPK-ERK pathway supports synaptic plasticity and long-term potentiation. The PLCgamma pathway drives calcium-dependent processes involved in synaptic strengthening. Taken together, TrkB signalling downstream of BDNF release is not a single event but a broad programme of transcriptional and post-translational changes that collectively amount to a more plastic, survival-competent neuronal state.
NGF acts in parallel through its own high-affinity receptor TrkA, following a comparable if partially distinct downstream cascade. TrkA signalling is particularly important for the cholinergic neurons of the basal forebrain, and its activation by NGF-inducing compounds is mechanistically relevant to the acetylcholine-dependent aspects of memory encoding and retrieval.
What the 2008 rat-hippocampus study actually measured
The most frequently cited primary data on Semax's neurotrophic mechanism comes from a 2008 Russian Academy of Sciences study that measured BDNF and NGF mRNA levels in the rat hippocampus and frontal cortex following a single intranasal Semax administration. The study used quantitative PCR to measure mRNA abundance, a molecular endpoint that indicates transcriptional activation, not the full chain of events leading to synaptic plasticity. What it found was a statistically significant and substantial increase in both transcripts, appearing within hours and persisting well beyond the expected plasma clearance of the peptide. The study is a strong demonstration of the neurotrophic induction mechanism; it is not, however, a demonstration of cognitive improvement in rats, let alone humans.
Enkephalinase inhibition — the second mechanistic arm
Semax does not act exclusively through the neurotrophic pathway. A secondary mechanism, sometimes overlooked in summaries focused on the BDNF story, is its inhibition of enkephalinase (the enzyme responsible for degrading endogenous opioid peptides including the enkephalins and endorphins). By slowing the breakdown of these endogenous modulators, Semax transiently elevates enkephalin tone in brain regions where enkephalin signalling has anxiolytic, mood-stabilising, and reward-related functions.
This second mechanism helps account for observations in the research literature that go beyond the purely cognitive. Reports of improved mood, reduced anxiety, and motivational effects in Semax research protocols are more plausibly attributed to enkephalin system modulation than to BDNF induction, which operates on a timescale incompatible with acute mood effects. The two mechanisms work in parallel and together produce a broader pharmacological profile than either alone.
What the evidence does not yet show: translation gaps to human cognition
The mechanistic case for Semax as a cognitive-enhancement research tool is coherent and based on well-replicated molecular findings. The human evidence base, by contrast, is far thinner. The compound has been studied clinically in Russia, primarily in post-stroke rehabilitation and attention research, and those trials show promising results on cognitive outcome measures. But the populations studied are clinically impaired rather than healthy, the methodology of many Eastern European trials from the 2000s would not meet current Western clinical-trial standards, and independent replication outside the originating research community is limited.
The distance between "reliably increases hippocampal BDNF mRNA in rats" and "reliably improves memory in healthy humans" is substantial. The detailed Semax mechanism and study summary on the primary reference site covers the published trial record in full, including the healthy-subject attention study from 2015. The honest summary is that the molecular evidence is strong, the translational evidence is encouraging but incomplete, and the cognitive claims that circulate in popular nootropic communities often run well ahead of what the published data actually supports.